Adjuvant chemotherapy

The phase 3 KEYNOTE-522 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has met one...


The European Commission ( EC ) has approved Keytruda , an anti-PD-1 therapy, as monotherapy or in combination with Platinum...


The European Commission has approved Talzenna ( Talazoparib ), an oral poly (ADP-ribose) polymerase ( PARP ) inhibitor, as monotherapy...


Neoadjuvant, or pre-surgical, treatment with Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) resulted in an overall major pathologic...


Role of aromatase inhibitors and Zoledronic acid ( Zometa ) as adjuvant treatment of premenopausal endocrine-responsive breast cancer patients is...


Although immune checkpoint inhibitors ( ICI ) have improved outcomes in some patients with Platinum-resistant metastatic urothelial carcinoma ( mUC...


The FDA ( Food and Drug Administration ) has approved Opdivo ( Nivolumab ) injection, for intravenous use for the...


The US Food and Drug Administration ( FDA ) has granted accelerated approval to Tecentriq ( Atezolizumab ) for the...



The European Commission ( EC ) has approved Opdivo ( Nivolumab ) for the treatment of locally advanced unresectable or...


Hepatocellular carcinoma ( HCC ) is responsible for over 600,000 deaths annually. In addition, hepatocellular carcinoma is characterized by its...


The FDA ( Food and Drug Administration ) has granted Priority Review for Atezolizumab ( anti-PD-L1; MPDL3280A ) for the...


The FDA ( Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) to treat the most common type...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Tecentriq ( Atezolizumab ) for the...


Little is known about the outcomes and prognostic factors of adjuvant chemotherapy for locally advanced penile squamous cell carcinoma after...


The prognostic value of BRAF and KRAS mutations in patients who have undergone resection for colon cancer and have been...


The Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 ( programmed death receptor-1...


Ovarian failure is a common toxic effect of chemotherapy. Studies of the use of gonadotropin-releasing hormone ( GnRH ) agonists...


Chemotherapy-induced alopecia ( CIA ) is a distressing adverse effect of many chemotherapy agents. The TC ( Docetaxel [ Taxotere...


PIK3CA mutations are common in breast cancer. The aim of a study was to evaluate the correlation of PIK3CA mutational...